{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T19:18:42Z","timestamp":1758050322774,"version":"3.44.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["canadianjournalofophthalmology.ca","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Ophthalmology"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.jcjo.2022.10.017","type":"journal-article","created":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T01:40:27Z","timestamp":1667266827000},"page":"e41-e45","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient-reported outcomes following a break in ophthalmic botulinum toxin therapy during the COVID-19 pandemic"],"prefix":"10.1016","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8294-443X","authenticated-orcid":false,"given":"Aaron","family":"Jamison","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maribel","family":"Favor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raman","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcjo.2022.10.017_bib0001","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.survophthal.2010.03.008","article-title":"Review and update of involuntary facial movement disorders presenting in the ophthalmological setting","volume":"56","author":"Ross","year":"2011","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.jcjo.2022.10.017_bib0002","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.survophthal.2011.02.005","article-title":"Reply to: Review and update of involuntary facial movement disorders presenting in the ophthalmological setting, \u201ceyelid myokymia","volume":"56","author":"Miller","year":"2011","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.jcjo.2022.10.017_bib0003","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/bjo.86.1.43","article-title":"Botulinum toxin treatment for hyperlacrimation secondary to aberrant regenerated seventh nerve palsy or salivary gland transplantation","volume":"86","author":"Keegan","year":"2002","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2022.10.017_bib0004","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/sj.eye.6700230","article-title":"Treatment of gustatory hyperlacrimation (crocodile tears) with injection of botulinum toxin into the lacrimal gland","volume":"16","author":"Montoya","year":"2002","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.jcjo.2022.10.017_bib0005","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1076\/orbi.22.3.193.15622","article-title":"The use of botulinum toxin A in the treatment of functional epiphora","volume":"22","author":"Whittaker","year":"2003","journal-title":"Orbit"},{"key":"10.1016\/j.jcjo.2022.10.017_bib0006","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/eye.2015.18","article-title":"Botulinum toxin injection for the treatment of epiphora in lacrimal outflow obstruction","volume":"29","author":"Ziahosseini","year":"2015","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.jcjo.2022.10.017_bib0007","article-title":"Lockdown Botox ban that's been torture for facial palsy patients after treatment for condition is deemed cosmetic and non-essential","author":"Calman","year":"2021","journal-title":"Daily Mail."},{"key":"10.1016\/j.jcjo.2022.10.017_bib0008","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1212\/WNL.37.4.616","article-title":"Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study","volume":"37","author":"Jankovic","year":"1987","journal-title":"Neurology"},{"key":"10.1016\/j.jcjo.2022.10.017_bib0009","series-title":"Treatment of movement disorders","first-page":"183","article-title":"Treatment of dystonia using botulinum toxin","author":"Brin","year":"1995"},{"key":"10.1016\/j.jcjo.2022.10.017_bib0010","first-page":"206","article-title":"Botulinum toxin treatment of hemifacial spasm and blepharospasm: objective response evaluation","volume":"47","author":"Thussu","year":"1999","journal-title":"Neurol India"},{"key":"10.1016\/j.jcjo.2022.10.017_bib0011","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/01.IOP.0000162429.97307.4D","article-title":"Assessment of blepharospasm surgery using an improved disability scale: study of 138 patients","volume":"21","author":"Grivet","year":"2005","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"10.1016\/j.jcjo.2022.10.017_bib0012","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1148\/radiology.177.3.2243969","article-title":"Epiphora: treatment by means of dacryocystoplasty with balloon dilation of the nasolacrimal drainage apparatus","volume":"177","author":"Munk","year":"1990","journal-title":"Radiology"},{"key":"10.1016\/j.jcjo.2022.10.017_bib0013","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1136\/bjo.80.12.1073","article-title":"Treatment selections of 239 patients with blepharospasm and Meige syndrome over 11 years","volume":"80","author":"Mauriello","year":"1996","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2022.10.017_bib0014","first-page":"363","article-title":"Long-term treatment of blepharospasm with botulinum toxin type A","volume":"4","author":"Nussgens","year":"1995","journal-title":"Ger J Ophthalmol"},{"key":"10.1016\/j.jcjo.2022.10.017_bib0015","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/WNF.0b013e3181c46f61","article-title":"Prospective, randomized, double-blind study, comparing botulinum toxins type A Botox and Prosigne for blepharospasm and hemifacial spasm treatment","volume":"33","author":"Quagliato","year":"2010","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.jcjo.2022.10.017_bib0016","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00702-005-0323-3","article-title":"NT 201 Blepharospasm Study Team. Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm","volume":"113","author":"Roggenkamper","year":"2006","journal-title":"J Neural Transm (Vienna)."},{"key":"10.1016\/j.jcjo.2022.10.017_bib0017","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/BF00941758","article-title":"Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm","volume":"235","author":"Nussgens","year":"1997","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jcjo.2022.10.017_bib0018","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1185\/030079905X36396","article-title":"Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm","volume":"21","author":"Bihari","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jcjo.2022.10.017_bib0019","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/ceo.13829","article-title":"Switchover study of onabotulinumtoxinA to incobotulinumtoxinA for facial dystonia","volume":"48","author":"Bladen","year":"2020","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.jcjo.2022.10.017_bib0020","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/ceo.12165","article-title":"Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm","volume":"42","author":"Ababneh","year":"2014","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.jcjo.2022.10.017_bib0021","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/mds.23658","article-title":"Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm\u2014a randomized trial","volume":"26","author":"Jankovic","year":"2011","journal-title":"Mov Disord"},{"key":"10.1016\/j.jcjo.2022.10.017_bib0022","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/mds.870120627","article-title":"DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A\u2014Dysport and Botox\u2014assuming a ratio of 4:1","volume":"12","author":"Sampaio","year":"1997","journal-title":"Mov Disord"},{"key":"10.1016\/j.jcjo.2022.10.017_bib0023","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.3109\/09638280903514697","article-title":"Evaluation and treatment of synkinesis with botulinum toxin following facial nerve palsy","volume":"32","author":"Toffola","year":"2010","journal-title":"Disabil Rehabil"}],"container-title":["Canadian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418222003349?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418222003349?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T20:11:38Z","timestamp":1757794298000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008418222003349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S0008418222003349"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjo.2022.10.017","relation":{},"ISSN":["0008-4182"],"issn-type":[{"type":"print","value":"0008-4182"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-reported outcomes following a break in ophthalmic botulinum toxin therapy during the COVID-19 pandemic","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjo.2022.10.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}